Fig. 4

The active tumor-targeting ability of BDM. (A) Schematic diagram of in vivo imaging experiment: Tumor-bearing C3H mice were treated with BD and BDM label with Cy5 (i.v., 80 µg/mL), and then the fluorescence images were taken at 1, 4, 8, 12 and 24 h after injection. (B) In vivo fluorescence images of SCC7 tumor-bearing C3H mice taken at different times. (C) Quantitative mean fluorescence intensities of tumors in different groups at various time points. (D) Represent ex vivo fluorescence images of tumors and main organs dissected from different group at 24 h post-injection. (E) Quantitative mean fluorescence intensities of ex vivo tumors in different groups at 24 h post-injection. (*, p < 0.05; **, p < 0.01; ***, p < 0.001, ns, not significant)